Clinical Data MSD, Eisai report setback in first-line kidney cancer trial PharmaphorumThe LITESPARK-012 trial saw no benefit when Welireg was added to treatment with Keytruda plus Lenvima for renal cell carcinoma.Clinical DataOncologyRead full story pharminent April 21, 2026 (Last updated: April 21, 2026) Pharmaphorum The LITESPARK-012 trial saw no benefit when Welireg was added to treatment with Keytruda plus Lenvima for renal cell carcinoma. Clinical DataOncologyRead full story Post navigation Previous: Gilead, Arcus tumble again in TIGIT, triggering 2 trial cullsNext: AACR 2026: Moderna, Revolution, Zymeworks and BeOne showcase new data Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
